Publication | Open Access

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Placebo-controlled Phase 3MedicineMetronomic TherapyGynecologyStandard First-line ChemotherapyPharmacotherapyAgo-ovar 12Cancer TreatmentOncologyRadiation OncologyGynecology OncologyOvarian Cancer